News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Rumored to be Exploring Sale of Ritalin, Clozaril and Exelon, Deal Could Bring in $300 Million



11/23/2016 5:52:31 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Novartis is reported to be weighing the sale of its Ritalin, Clozaril and Exelon drugs as the Swiss giant cuts back on treatments for the central nervous system in favor of generics and other products.

The sale of the drugs, which treat attention-deficit-hyperactivity disorder, schizophrenia and Alzheimer’s disease, respectively, could command a price of more than $300 million and draw offers from other pharmaceutical companies, according to people familiar with the matter. They asked not to be identified because the deliberations are private.

Read at SF Gate


comments powered by Disqus
SF Gate
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES